For following the competition: what moved in each program, several studies read as one move.
- plamotamab
- Anti-CLDN6/CD3 Bispecific Antibody XmAb541
- Anti-B7-H3/CD28 Bispecific Antibody XmAb808
- + 2 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Xencor to watchlistEvery Monday by email · turn it off any timePro · free during the beta